Shukra Pharmaceuticals is locked in its upper circuit at RS. 19.91, rising by 0.39 points or 2.00% from its previous closing of RS. 19.52 on the BSE.

The stock opened at RS. 19.16 and recorded a high of RS. 19.91 and a low of RS. 19.16. A total of 5,49,899 shares have been traded so far.

Classified under the BSE group 'XT', the stock with a face value of RS. 1 has marked a 52-week high of RS. 27.15 on March 5, 2025, and a 52-week low of RS. 5.75 on November 21, 2024. Over the past week, the scrip has seen a high of RS. 21.14 and a low of RS. 19.16. The company’s current market capitalization stands at RS. 871.82 crore.

Promoters hold 50.96% of the company’s shares, while institutional investors and non-institutional investors hold 0.11% and 48.93% respectively.

In a major development, Shukra Pharmaceuticals has signed a service agreement with APITCO (a PSU) to collaborate on various government healthcare projects. The partnership leverages APITCO’s sectoral expertise and Shukra’s capabilities in project management, healthcare services, and training.

Under the agreement, Shukra will serve as a business associate, healthcare project management consultant, and training provider. Projects will be executed under well-defined service level agreements (SLAs) with clear scope, timelines, deliverables, and performance standards.

Shukra Pharmaceuticals continues to grow as a forward-thinking organization, with a strong focus on sustainability and impactful healthcare solutions.